What is the next catalyst for Pyxis Oncology (PYXS)?

The next dated event is Phase 1/2 interim results for MICVO, expected Q4 2026, as stated by the company. Also ahead: Phase 1 long-term results for MICVO, expected H1 2027.

How long will Pyxis Oncology's cash last?

Pyxis Oncology has said its cash will fund operations into the first half of 2028 (guidance as of November 5, 2026). It reported $55.6 million in cash as of September 30, 2026.

PYXSPyxis Oncology, Inc.

⚡

Pyxis Oncology Reports Third Quarter 2026 Financial Results - GlobeNewswire

GlobeNewswire · Nov 5, 12:00 PM

ChallengedLast material event Sep 9, 2026 · Updated Oct 25, 2026

Pyxis plans to start a 500-patient Phase 3 trial of MICVO in previously treated head and neck cancer in mid-2027 after a 36% confirmed response rate in Phase 1; an October offering raised $102.8 million and extended cash into the first half of 2028

Pyxis Oncology is a clinical-stage company developing micvotabart pelidotin (MICVO), an antibody-drug conjugate that targets a protein in the tissue around tumors, for head and neck cancer; it is not approved.

Pyxis' case rests on MICVO, an antibody-drug conjugate that targets the tissue around tumors, which gave a 36% confirmed response rate in 33 previously treated head and neck cancer patients. An End of Phase 2 meeting with FDA on dose is expected in the first quarter of 2027, ahead of Headliner, a roughly 500-patient Phase 3 planned for mid-2027. Grade 3 or higher treatment-related side effects hit 54% of patients, and an October offering raised $102.8 million net, expected to fund Pyxis into the first half of 2028.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

FDA agrees on the Phase 3 doseAwaiting evidenceEnd of Phase 2 meeting (first quarter of 2027).Next: End of Phase 2 meeting (first quarter of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Headliner starts in mid-2027Awaiting evidenceTrial start (mid-2027).Next: Trial start (mid-2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Survival data support the response rateAwaiting evidenceUpdated overall survival data (first half of 2027).Next: Updated overall survival data (first half of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts into the first half of 2028SupportedQ3 cash balance; shareholder vote on authorized shares.Next: Q3 cash balance; shareholder vote on authorized shares.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

End of Phase 2 meeting with FDA

Tests: FDA agrees on the Phase 3 dose

First quarter of 2027

Does FDA agree on the MICVO dose so Headliner can start in mid-2027?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentClinical

-13.1%Sep 9, 2026

Pyxis plans to start a 500-patient Phase 3 trial of MICVO in previously treated head and neck cancer in mid-2027 after a 36% confirmed response rate in Phase 1; an October offering raised $102.8 million and extended cash into the first half of 2028

ChallengedClinical

-48.7%Dec 18, 2025

MICVO Phase 1 monotherapy: 46% ORR in 2L+ R/M HNSCC

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

R/M HNSCC· post-platinum and anti-PD-(L)1

MICVO · 3 upcoming · 3 completed

End-of-Phase Meeting

Q1 2027

Phase 1 Data: Long-term

H1 2027

Phase 3 Study InitiationHeadliner™Pivotal

Mid 2027

R/M HNSCC· with pembrolizumab

MICVO · 1 upcoming · 1 completed

Phase 1/2 Data: Interim

Q4 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Pyxis Oncology (PYXS) investment thesis intact?: It is under pressure. Readouts currently rates the Pyxis Oncology Thesis Challenged. Pyxis plans to start a 500-patient Phase 3 trial of MICVO in previously treated head and neck cancer in mid-2027 after a 36% confirmed response rate in Phase 1; an October offering raised $102.8 million and extended cash into the first half of 2028.
What is the next catalyst for Pyxis Oncology (PYXS)?: The next dated event is Phase 1/2 interim results for MICVO, expected Q4 2026, as stated by the company. Also ahead: Phase 1 long-term results for MICVO, expected H1 2027.
How long will Pyxis Oncology's cash last?: Pyxis Oncology has said its cash will fund operations into the first half of 2028 (guidance as of November 5, 2026). It reported $55.6 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Head and neck squamous cell carcinoma: Corbus Pharmaceuticals (CRBP)Coherus Oncology (CHRS)Alpha Tau Medical (DRTS)Immutep (IMMP)Summit Therapeutics (SMMT)

Disease areas: Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

6 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.